October 2nd 2019
Davendra Sohal, MD, MPH, discusses the SWOG S1505 data and other emerging areas of research in pancreatic cancer.
September 27th 2019
David H. Ilson, MD, PhD, discusses the utility of TAS-102 in gastric and GEJ adenocarcinoma as well as other encouraging research in these spaces.
September 26th 2019
Raja Mudad, MD, FACP, discussed the available EGFR inhibitors and sequencing challenges for patients with EGFR-mutant non-small cell lung cancer.
September 25th 2019
Hossein Borghaei, DO, discusses pivotal and ongoing trials driven by biomarkers in lung cancer.
September 24th 2019
Kanwarpal S. Kahlon, MD, discusses current treatment options for patients with aplastic anemia, immune thrombocytopenic purpura, and thrombotic thrombocytopenic purpura, as well as future research for the field.
Konstantinos Leventakos, MD, discusses updates in personalized medicine for patients with stage III lung cancer.
September 23rd 2019
Paul Kelly Marcom, MD, discusses the role of genomic testing in breast cancer.
September 20th 2019
Gary J. Schiller, MD, discusses therapeutic advances, the importance of genomic testing, and other agents in the pipeline for acute myeloid leukemia.
September 19th 2019
Arek Z. Dudek, MD, PhD, discusses the research surrounding osimertinib in the treatment of patients with EGFR-positive non–small cell lung cancer.
September 18th 2019
Michael Wang, MD, discusses how the mantle cell lymphoma paradigm is facing a time of exploration, as researchers examine different therapeutic options beyond chemotherapy.
September 16th 2019
Joseph Leach, MD, a medical oncologist at Minnesota Oncology, discussed the emergence of ALK inhibitors in lung cancer and the importance of testing for such molecular abnormalities.
September 15th 2019
Laura C. Michaelis, MD, discusses the currently approved JAK inhibitors and the future landscape for myelofibrosis, as well as treatment considerations for graft-versus-host disease.
September 13th 2019
John F. DiPersio, MD, PhD, discusses the challenges in research surrounding targeted cellular therapies for acute myeloid leukemia
Ruben Mesa, MD, discusses the JAKARTA and JAKARTA-2 studies and the implications their data have on the field of myelofibrosis.
September 11th 2019
Robert A. Kratzke, MD discusses the excitement surrounding immunotherapy and the work being done with biomarkers to assist in making optimal treatment decisions in lung cancer.
September 5th 2019
Manish Patel, DO, discusses advances and remaining questions with chemoimmunotherapy combinations in nonsquamous metastatic non–small cell lung cancer.
Amrita Krishnan, MD, highlights recent research in relapsed/refractory multiple myeloma.
September 3rd 2019
David S. Snyder, MD, highlights agents currently undergoing clinical trials for polycythemia vera and myelofibrosis as well as how to most effectively treat patients using transplantation.
Encorafenib (Braftovi) plus binimetinib (Mektovi) had superior overall survival and progression-free survival compared with encorafenib or vemurafenib (Zelboraf) alone in patients with BRAF V600–mutant melanoma.
August 30th 2019
Samir Parekh, MBBS, highlights ongoing research regarding personalized medicine for multiple myeloma.